Decades of research coming good in Amgen's early oncology pipeline, says Dirk Nagorsen

When it comes to long-term investment in pharma stocks, looking at pipeline assets at a pre-clinical or early clinical stage gives as good a clue as any as to where the value lies.

This is particularly true at a time when big companies are having to pay such high prices for acquisitions, especially in oncology, which – fortunately for Amgen (Nasdaq: AMGN) – is where a lot of the US biotech company’s most promising early candidates are.

Promise in solid tumors